Filed by: Bergen Brunswig Corporation. This
                                   Communication is filed pursuant to Rule 425
                                   under The Securities Act of 1933, as amended,
                                   and deemed filed pursuant to Rule 14a-12 of
                                   the Securities Exchange Act of 1934.

                                   Subject Company: Bergen Brunswig Corporation
                                   Commission File Number: 1-5110


FORWARD-LOOKING STATEMENTS

The following communications contain certain "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances. Actual results may vary materially from the expectations
contained in the forward-looking statements. The forward-looking statements
herein include statements addressing future financial and operating results of
AmeriSource and Bergen Brunswig and the timing, benefits and other aspects of
the proposed merger.

The following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: inability to
obtain, or meet conditions imposed for, governmental approvals for the
transaction; failure of the stockholders of AmeriSource and Bergen Brunswig to
approve the merger; the risk that the businesses of AmeriSource and Bergen
Brunswig will not be integrated successfully; failure to obtain and retain
expected synergies; and other economic, business, competitive and/or regulatory
factors affecting the businesses of AmeriSource and Bergen Brunswig generally.
More detailed information about these factors is set forth in AmeriSource's and
Bergen Brunswig's filings with the Securities and Exchange Commission, including
each of their Annual Reports on Form 10-K for fiscal 2000 and their most recent
quarterly reports on Form 10-Q. AmeriSource and Bergen Brunswig are under no
obligation to (and expressly disclaim any such obligation to) update or alter
their forward-looking statements whether as a result of new information, future
events or otherwise.

ADDITIONAL INFORMATION

In connection with their proposed merger, AmeriSource and Bergen Brunswig will
file a joint proxy statement/prospectus with the Securities and Exchange
Commission. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE, BECAUSE IT WILL CONTAIN
IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of
the joint proxy statement/prospectus (when available) and other documents filed
by AmeriSource and Bergen Brunswig at the Securities and Exchange Commission's
web site at www.sec.gov. The joint proxy statement/prospectus and such other
documents may also be obtained for free from AmeriSource or from Bergen Brunswig
by directing such request to AmeriSource Health Corporation, General Counsel,
1300 Morris Drive, Suite 100, Chesterbrook, Pennsylvania 19087-5594, Telephone:
(610) 727-7000; or to Bergen Brunswig Corporation, Attention: Corporate
Secretary, 4000 Metropolitan Drive, Orange, California 92868-3510, Telephone:
(714) 385-4000.

PARTICIPANTS IN SOLICITATION

AmeriSource and Bergen Brunswig and their respective directors, executive
officers and other members of their management and employees may be deemed to be
participants in the solicitation of proxies from their respective stockholders
in connection with the proposed merger. Information concerning AmeriSource's
participants in the solicitation is set forth in AmeriSource's Current Report on
Form 8-K filed with the Securities and Exchange Commission on March 19, 2001,
and information concerning Bergen Brunswig's participants in the solicitation is
set forth in Bergen Brunswig's Current Report on Form 8-K filed with the
Securities and Exchange Commission on March 19, 2001.



(BW)(PA-AMERISOURCE/BERGEN)(AAS)(BBC) AmeriSource and Bergen Brunswig Receive
Request for Additional Information From Federal Trade Commission

     VALLEY FORGE, Pa. & ORANGE, Calif.--(BW HealthWire)--May 7, 2001--
AmeriSource Health Corporation (NYSE:AAS) and Bergen Brunswig Corporation
(NYSE:BBC) today announced that, as anticipated, they have received a request
for additional information and documentary material from the Federal Trade
Commission in connection with their previously announced plan to merge the two
companies.

     This "second request" extends the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 during which the FTC is
permitted to review the transaction.

     On March 19, 2001, AmeriSource and Bergen Brunswig announced that they had
entered into a merger agreement to create a new company named AmeriSource-Bergen
Corporation.

     Under the terms of the agreement, each share of Bergen Brunswig common
stock will be converted into 0.37 shares of AmeriSource-Bergen common stock and
each share of AmeriSource common stock will be converted into one share of
AmeriSource-Bergen common stock.

     About AmeriSource

     AmeriSource Health Corporation, with approximately $14 billion in
annualized operating revenue, is a leading distributor of pharmaceutical and
related healthcare products and services, and the industry's largest provider of
pharmaceuticals to acute care/health systems customers.

     Headquartered in Valley Forge, PA, the Company serves its base of about
15,000 customer accounts through a national network of 22 strategically located
drug distribution facilities. For news and additional information about the
company, visit its web site at www.amerisource.com.

     About Bergen Brunswig

     Bergen Brunswig Corporation, headquartered in Orange County, California, is
a leading supplier of pharmaceuticals and specialty healthcare products as well
as information management solutions and consulting services.

     With $22 billion in annualized operating revenues, Bergen's customers
include the nation's healthcare providers (hospitals, nursing homes,
physicians), drug stores, manufacturers and patients.

     Through its Drug Company's 30 distribution centers and its other subsidiary
companies, Bergen provides product distribution, logistics, pharmacy management
programs, and Internet fulfillment strategies designed to reduce costs and
improve patient outcomes across the entire healthcare spectrum. Bergen Brunswig
press releases are available on the Company's web site at
www.bergenbrunswig.com.

     Forward-Looking Statements

     The foregoing communication contains certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These statements are based on
management's current expectations and are subject to uncertainty and changes in
circumstances.

     Actual results may vary materially from the expectations contained in the
forward-looking statements. The forward-looking statements herein include
statements addressing future financial and operating results of AmeriSource and
Bergen Brunswig and the timing, benefits and other aspects of the proposed
merger.

     The following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: inability to
obtain, or meet conditions imposed for, governmental approvals for the
transaction; failure of the stockholders of AmeriSource and Bergen Brunswig to
approve the merger; the risk that the businesses of AmeriSource and Bergen
Brunswig will not be integrated successfully; failure to obtain and retain
expected synergies; and other economic, business, competitive and/or regulatory
factors affecting the businesses of AmeriSource and Bergen Brunswig generally.

     More detailed information about these factors is set forth in AmeriSource's
and Bergen Brunswig's filings with the Securities and Exchange Commission,
including each of their Annual Reports on Form 10-K for fiscal 2000 and their
most recent quarterly reports on Form 10-Q.

     AmeriSource and Bergen Brunswig are under no obligation to (and expressly
disclaim any such obligation to) update or alter their forward-looking
statements whether as a result of new information, future events or otherwise.

     Additional Information

     In connection with their proposed merger, AmeriSource and Bergen Brunswig
will file a joint proxy statement/prospectus with the Securities and Exchange
Commission. Investors and security holders are advised to read the joint proxy
statement/prospectus when it becomes available, because it will contain
important information.

     Investors and security holders may obtain a free copy of the joint proxy
statement/prospectus (when available) and other documents filed by AmeriSource
and Bergen Brunswig at the Securities and Exchange Commission's web site at
www.sec.gov.

     The joint proxy statement/prospectus and such other documents may also be
obtained for free from AmeriSource or from Bergen Brunswig by directing such
request to AmeriSource Health Corporation, General Counsel, 1300 Morris Drive,
Suite 100, Chesterbrook, Pennsylvania 19087-5594, Telephone: 610/727-7000; or to
Bergen Brunswig Corporation, Attention: Corporate Secretary, 4000 Metropolitan
Drive, Orange, California 92868-3510, Telephone: 714/385-4000.

     Participants in Solicitation

     AmeriSource and Bergen Brunswig and their respective directors, executive
officers and other members of their management and employees may be deemed to be
participants in the solicitation of proxies from their respective stockholders
in connection with the proposed merger.

     Information concerning AmeriSource's participants in the solicitation is
set forth in AmeriSource's Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 19, 2001, and information concerning Bergen
Brunswig's participants in the solicitation is set forth in Bergen Brunswig's
Current Report on Form 8-K filed with the Securities and Exchange Commission on
March 19, 2001.

     --30--

     CONTACT: AmeriSource Health Corporation
              Michael N. Kilpatric,610/727-7118
              mkilpatric@amerisource.com
               or
              Bergen Brunswig Corporation
              Donna Dolan, 714/385-4226
              donna.dolan@bergenbrunswig.com